Vistagen Therapeutics, Inc. 8-K

What Happened

• On April 22, 2026 Vistagen Therapeutics issued a press release stating the U.S. Food and Drug Administration sent a "Study May Proceed" letter under the company’s IND for refisolone nasal spray. The letter allows Vistagen to pursue further Phase 2 clinical development in the U.S. for refisolone, a non-hormonal, non-systemic candidate for moderate to severe vasomotor symptoms (hot flashes) due to menopause. The 8-K reporting this press release was filed April 28, 2026 (Exhibit 99.1).

Key Details

• FDA "Study May Proceed" letter received and announced April 22, 2026.
• Drug candidate: refisolone nasal spray — non-hormonal, non-systemic; targeted indication: moderate to severe vasomotor symptoms due to menopause.
• Company cites prior successful exploratory Phase 2a clinical studies conducted in Mexico for menopausal hot flashes and premenstrual dysphoric disorder (PMDD).
• 8-K filed April 28, 2026; signed by Shawn K. Singh, President and CEO.

Why It Matters

• The FDA letter removes a regulatory step that enables Vistagen to commence additional U.S. Phase 2 work on refisolone, advancing the program toward potential later-stage development.
• For investors, this is a material clinical development update (early-stage): it shows regulatory acceptance to proceed but is not an approval and does not guarantee clinical or commercial success.
• The filing did not include financial statements or new financial disclosures; it primarily reports the regulatory/clinical milestone and the related press release.